Stocks and Investing Stocks and Investing
Tue, January 7, 2025
[ Tue, Jan 07th ] - MSN
10 penny stocks that can offer investors promisin .. erm potential, should you invest in January 2025?
[ Tue, Jan 07th ] - MSN
Melius Upgrades Cisco (CSCO) to Buy, Highlights AI and Networking Upside
[ Tue, Jan 07th ] - Kiplinger
Stock Market Today: Stocks Dragged Down by Strong Data
[ Tue, Jan 07th ] - MSN
2 Assets That Will Soar in Value During Trump's Presidency, According to Grant Cardone
[ Tue, Jan 07th ] - MSN
3 Ways Mark Cuban and Other Millionaires and Billionaires Protect Their Wealth
[ Tue, Jan 07th ] - MarketWatch
Stock Market Today: Dow falls over 250 points, Na .. ields surge after job-openings, ISM services data
[ Tue, Jan 07th ] - MSN
Should Kimberly-Clark Corporation (NYSE:KMB) Be In Your Early Retirement Portfolio?
[ Tue, Jan 07th ] - MSN
Mexico's new taxes on imports will benefit these 2 e-commerce stocks
[ Tue, Jan 07th ] - MarketWatch
Good news on the economy likely shifts to bad news from here, says BofA Global
[ Tue, Jan 07th ] - MSN
Is New Found Gold Corp. (NFGC) Among the Best Canadian Penny Stocks to Buy According to Analysts?
[ Tue, Jan 07th ] - MSN
Here's Why it is Worth Investing in Allegion Stock Right Now
[ Tue, Jan 07th ] - Investing
US stocks fall as Treasury yields rise on data flagging fresh inflation concerns
[ Tue, Jan 07th ] - MSN
Piper initiates on soda stocks; Pepsi, Coca-Cola 'overweight,' Dr Pepper 'neutral'
[ Tue, Jan 07th ] - Yahoo
Missile maker MBDA buys Safran's stake in rocket-engine supplier Roxel
[ Tue, Jan 07th ] - Kiplinger
Nvidia CES 2025 Updates: What Investors Need to Know
[ Tue, Jan 07th ] - Kiplinger
Meta Adds Dana White to Its Board, Ends Fact-Checking: What to Know
[ Tue, Jan 07th ] - Kiplinger
Why McDonald's Is Still a Buy After Rolling Back DEI Initiatives
[ Tue, Jan 07th ] - WOPRAI
40 Earnings Releases for Jan 07th, 2025
[ Tue, Jan 07th ] - MSN
Is It Worth Investing in Alibaba (BABA) Based on Wall Street's Bullish Views?
[ Tue, Jan 07th ] - Investopedia
Is Forex Buy-and-Hold Trading the Investing Strategy You've Been Missing?
[ Tue, Jan 07th ] - MSN
Unlocking value: These 6 mutual funds offered ove .. nual returns in last 10 years; should you invest?
[ Tue, Jan 07th ] - MarketWatch
Stock Market Today: Dow pares earlier gains following jobs data
[ Tue, Jan 07th ] - TechRepublic
Microsoft to Invest $80 Billion in AI Data Centers in Fiscal 2025
[ Tue, Jan 07th ] - MSN
3 big gold investing mistakes to avoid in 2025
[ Tue, Jan 07th ] - MSN
3 Undervalued Companies Warren Buffett Invested In During 2024: Should You Buy These Stocks?
[ Tue, Jan 07th ] - MSN
Build a Bulletproof Portfolio with These Three Diversified Dividend Stocks
[ Tue, Jan 07th ] - MSN
UK sees surge in crypto ownership with 7 million Brits investing in digital assets
[ Tue, Jan 07th ] - Sky
Money blog: High street chain with 364 stores 'accelerating closures' due to budget
[ Tue, Jan 07th ] - MSN
Top 3 Contra Mutual Funds With Best SIP Returns i .. nvestment in No. 1 fund is now worth Rs 12,00,878
[ Tue, Jan 07th ] - MSN
Here's Why MannKind Corporation (NASDAQ:MNKD) Is Among the Best Diabetes Stocks to Buy Under $10

Here's Why MannKind Corporation (NASDAQ:MNKD) Is Among the Best Diabetes Stocks to Buy Under $10


Published on 2025-01-07 06:41:36 - MSN
  Print publication without navigation

  • We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at where MannKind Corporation (NASDAQ:MNKD) stands against the other diabetes stocks.

The article from MSN Money discusses why MannKind Corporation (NASDAQ: MNKD) is considered one of the best diabetes stocks to buy under $10. It highlights MannKind's focus on developing inhaled insulin therapies, specifically mentioning their product Afrezza, which is an ultra-rapid-acting inhaled insulin. The article points out that MannKind has shown promising clinical results, potentially offering a more convenient alternative to traditional insulin injections. Additionally, the company's stock is noted for its affordability, trading under $10, which makes it accessible for investors looking for growth in the diabetes treatment sector. The piece also mentions MannKind's strategic partnerships and ongoing research, suggesting a positive outlook for future revenue growth and market expansion. However, it also advises investors to consider the risks associated with biotech investments, including regulatory hurdles and competition.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/savingandinvesting/here-s-why-mannkind-corporation-nasdaq-mnkd-is-among-the-best-diabetes-stocks-to-buy-under-10/ar-AA1x2MG6 ]
Contributing Sources